PharmAbcine announces a research collaboration with LegoChem Biosciences
News provided by
Share this article
Share this article
DAEJEON, South Korea, Jan. 11, 2021 /PRNewswire/ PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company has entered into a research collaboration agreement with LegoChem Biosciences Inc. (KOSDAQ: 141080ks), a biopharmaceutical company focusing on the research and development of ADCs (Antibody-Drug Conjugates) in South Korea.
Under the agreement, PharmAbcine will provide PMC-403, a preclinical pipeline, to LCB so LCB can conduct a combination research using PMC-403 and LCB s proprietary ADC. This preclinical study will allow both parties to evaluate the efficacy of the combination therapy in solid tumors.